Stocktoria
Cartesian Therapeutics, Inc. RNAC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-06-22
Cartesian Therapeutics, Inc. statistics & valuation
Market cap$276.8M
P / S99.0×
Net margin-4658.6%
FCF margin-2838.6%
Net cash$125.1M
Enterprise value USD$151.6M
Earnings yield EBIT/EV-94.6%
Return on capital-50.9%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -5127.1% | -112.8% | -332.3% | 13.1% | -5.4% | -342.4% | -785.6% | -7200.7% | -30813.5% | -428.9% |
| Net margin | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -448.0% |
| FCF margin | -2838.6% | -84.2% | -197.5% | -29.6% | -72.2% | 205.3% | -771.0% | -6649.5% | -25487.4% | -251.7% |
| Return on assets | -44.0% | -17.8% | -72.0% | 21.3% | -16.1% | -41.6% | -55.6% | -146.9% | -64.6% | -40.5% |
| Return on equity | 103.2% | 1138.3% | 49.9% | 37.7% | -114.1% | 382.5% | -659.2% | 1205.9% | -126.1% | -65.9% |
| Debt / equity | -0.00× | — | — | — | — | — | — | — | — | — |
| Current ratio | 8.65 | 9.43 | 1.33 | 5.91 | 2.00 | 1.86 | 2.77 | 1.20 | 8.99 | 6.33 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.